» Articles » PMID: 36506732

Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity

Overview
Specialty Oncology
Date 2022 Dec 12
PMID 36506732
Authors
Affiliations
Soon will be listed here.
Abstract

Significance: We found that duloxetine has potent OCT2-inhibitory properties and can diminish excessive accumulation of oxaliplatin into DRG neurons. In addition, pre-treatment of mice with duloxetine prevented OIPN without significantly altering the plasma pharmacokinetics and antitumor properties of oxaliplatin. These results suggest that intentional inhibition of OCT2-mediated transport by duloxetine can be employed as a prevention strategy to ameliorate OIPN without compromising the effectiveness of oxaliplatin-based treatment.

Citing Articles

Contribution and expression of renal drug transporters in renal cell carcinoma.

Zuo Y, Li T, Yang S, Chen X, Tao X, Dong D Front Pharmacol. 2025; 15:1466877.

PMID: 40034145 PMC: 11873565. DOI: 10.3389/fphar.2024.1466877.


Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Induced Neuropathy and Mitochondrial Toxicity: Limitations of the Poly-γ Hypothesis and the Potential Roles of Autophagy and Drug Transport.

Haynes J, Joshi A, Larue R, Eisenmann E, Govindarajan R Pharmaceutics. 2025; 16(12.

PMID: 39771570 PMC: 11677988. DOI: 10.3390/pharmaceutics16121592.


Vascular dysfunction is at the onset of oxaliplatin-induced peripheral neuropathy symptoms in mice.

Taib S, Durand J, Dehais V, Boulay A, Martin S, Blugeon C Life Sci Alliance. 2024; 8(2).

PMID: 39578077 PMC: 11584327. DOI: 10.26508/lsa.202402791.


Targeting dorsal root ganglia for chemotherapy-induced peripheral neuropathy: from bench to bedside.

Ege E, Briggi D, Vu P, Cheng J, Lin F, Xu J Ther Adv Neurol Disord. 2024; 17:17562864241252718.

PMID: 39318973 PMC: 11421407. DOI: 10.1177/17562864241252718.


Duloxetine prevents bortezomib and paclitaxel large-fiber chemotherapy-induced peripheral neuropathy (LF-CIPN) in sprague dawley rats.

Mansooralavi N, Khomula E, Levine J Mol Pain. 2023; 19:17448069231185694.

PMID: 37338165 PMC: 10288414. DOI: 10.1177/17448069231185694.

References
1.
Feng B, Hurst S, Lu Y, Varma M, Rotter C, El-Kattan A . Quantitative prediction of renal transporter-mediated clinical drug-drug interactions. Mol Pharm. 2013; 10(11):4207-15. DOI: 10.1021/mp400295c. View

2.
Wang S, Calderon J, Wang G . Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner. Anesthesiology. 2010; 113(3):655-65. DOI: 10.1097/ALN.0b013e3181e89a93. View

3.
Lunn M, Hughes R, Wiffen P . Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014; (1):CD007115. PMC: 10711341. DOI: 10.1002/14651858.CD007115.pub3. View

4.
Suhre W, Ekins S, Chang C, Swaan P, Wright S . Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol Pharmacol. 2005; 67(4):1067-77. DOI: 10.1124/mol.104.004713. View

5.
Marks D, Shah M, Patkar A, Masand P, Park G, Pae C . Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol. 2010; 7(4):331-6. PMC: 2811866. DOI: 10.2174/157015909790031201. View